# Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

> **NCT03965208** · PHASE4 · UNKNOWN · sponsor: **Legacy Health System** · enrollment: 34 (estimated)

## Conditions studied

- Extracorporeal Membrane Oxygenation Complication
- Anticoagulants

## Interventions

- **DRUG:** Bivalirudin
- **DRUG:** Unfractionated heparin

## Key facts

- **NCT ID:** NCT03965208
- **Lead sponsor:** Legacy Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-23
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2019-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03965208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03965208, "Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03965208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*